San Francisco 49ers head coach Kyle Shanahan made an appearance at the team’s opening training camp practice Sunday, watching from the sideline for roughly 30 minutes as he continues recovering from significant injuries sustained in a car crash near his Northern California home earlier this month.

A serious accident with a long list of injuries

Shanahan suffered a broken nose, three broken ribs, a broken hand and a severe concussion, along with more than 40 stitches to his face, in a two-car collision on the evening of July 14 near Palo Alto’s Stanford Shopping Center, according to multiple reports. Shanahan collided with an SUV; the other driver was not injured, according to ESPN’s Adam Schefter and Nick Wagoner. Drugs and alcohol were not involved in the crash, and no citations were issued to either driver.

Palo Alto police Lt. Nicholas Martinez confirmed both drivers were cooperative with responding officers, though the department declined to specify what caused the collision or assign fault. “We do not release information regarding the cause of the collision,” Martinez said, citing the department’s standard procedures for such cases. Paramedics transported Shanahan to a local hospital following the crash, where he remained for much of the night before being released.

The team confirms the injuries publicly

The 49ers publicly confirmed the crash and Shanahan’s injuries in a statement released Saturday morning, ahead of general manager John Lynch’s opening training camp press conference. The team said Shanahan sustained non-life-threatening injuries and would “participate in team activities on a limited basis” while he recovers, adding that both Shanahan and the organization wanted to thank the first responders involved in the incident. The statement confirmed that assistant head coach and offensive line coach Chris Foerster, along with the team’s coordinators, would assume head coaching responsibilities during Shanahan’s recovery.

Lynch addresses the recovery timeline

Speaking to reporters Saturday, Lynch confirmed Shanahan’s concussion and broken ribs and nose, though he did not initially mention the hand injury. He said the team expects Shanahan to be ready to coach the 49ers’ Week 1 opener against the Los Angeles Rams on Sept. 10 in Melbourne, Australia, though Shanahan will remain in a concussion recovery process similar to the protocol used for players until doctors clear him for full coaching duties. “He did suffer a concussion in the accident, has some lingering effects from that concussion,” Lynch said, adding that while the team doesn’t have a formal concussion protocol specifically designed for coaching staff, using the player protocol as a model has proven helpful. Lynch expressed confidence that Shanahan’s recovery would progress well ahead of the season opener, telling reporters, “I think the expectation is that long before that, he’ll be better.”

A collective effort in Shanahan’s absence

With training camp underway, a four-person coaching group is sharing head coaching responsibilities in Shanahan’s absence. Foerster is expected to serve as the de facto sideline head coach during the team’s three preseason games, scheduled for Aug. 14 against the Tennessee Titans, Aug. 21 against the Los Angeles Chargers, and Aug. 28 against the Las Vegas Raiders. He will be supported by defensive coordinator Raheem Morris, offensive coordinator Klay Kubiak and special teams coordinator Brant Boyer as the group collectively leads the team through camp and the preseason schedule. Lynch expressed confidence in that arrangement during his press conference, saying the team’s internal culture would carry it through the transition and that Foerster was well equipped to handle the added responsibility, even as the effort remains a shared one among the coaching staff.

Shanahan shows up anyway

Despite being sidelined from full coaching duties, Shanahan couldn’t stay away from the team’s first camp practice Sunday. He stood alongside Lynch, positioned behind the secondary, and watched most of the team’s 11-on-11 drills before stepping away after about 30 minutes. Veteran left tackle Trent Williams said he wasn’t surprised to see his head coach on the field despite the recommendation to rest. “I knew it would be tough to keep him away from there,” Williams told reporters after practice, adding that Shanahan isn’t the type of person who finds it easy to sit out and let others handle things.

Star linebacker Fred Warner offered a similarly light-hearted reaction to Shanahan’s appearance, telling reporters simply, “I know he couldn’t stay away.” Williams also reflected on how he first learned about Shanahan’s accident, saying he found out through social media Saturday rather than receiving a more alarming phone call, which he said made processing the news somewhat easier once he understood Shanahan was going to be okay.

Support from around the league

Shanahan has also received well wishes from coaching colleagues around the NFL. Los Angeles Rams coach Sean McVay, who worked alongside Shanahan as an assistant coach in Washington earlier in both of their careers, said he had spoken with Shanahan directly since the accident. McVay praised his fellow NFC West coach’s outlook on the situation and expressed hope for a smooth recovery, while noting how relieved he was that the crash hadn’t resulted in a worse outcome.

With training camp now underway and the 49ers working through a three-game preseason slate in August, all eyes will remain on Shanahan’s recovery timeline heading into the team’s season opener against the Rams in Australia. Lynch has said the team will continue to prioritize a full and proper recovery over any specific date, following medical guidance similar to the protocol used for players who suffer concussions. Whether Shanahan is able to return to full coaching duties before the preseason games begin, during the preseason itself, or closer to the regular-season opener remains uncertain, though both Lynch and Shanahan’s teammates have expressed optimism that he will be ready when the 49ers open their season in Melbourne on Sept. 10.

Laurus Labs shares jumped 4.05% to Rs 1,666 in Monday’s trading session after the company reported a stellar performance for the June 2026 quarter. The rally was fueled by a 126% year-on-year surge in net profit and 29% revenue growth, driven by strong CDMO performance and steady demand for affordable medicines.

According to the company’s regulatory filing, consolidated net profit for Q1FY27 stood at Rs 368 crore, compared with Rs 163 crore in the same quarter last year, marking a sharp 126% YoY growth. Revenue from operations increased 29% year-on-year to Rs 2,026 crore from Rs 1,570 crore in the corresponding period.

Laurus Labs highlighted that growth during the quarter was led by increased commercial projects in its Contract Development and Manufacturing Organisation (CDMO) segment, along with steady momentum in its affordable medicines portfolio.

The company reported EBITDA of Rs 644 crore, translating into a margin of 31.8%, an expansion of 7 percentage points compared with the previous year. The improvement was driven by higher CDMO contribution, better business mix, and operational efficiencies.

Gross margins also improved by more than 3 percentage points to 62.7%, reflecting stronger product mix and enhanced profitability.

Expansion plans remain on track

Laurus Labs continued to invest in expanding its manufacturing capabilities and developing niche technology platforms, with capital expenditure during the quarter accounting for 19% of sales.
The company said its planned capital expenditure for FY27 and FY28 remains on schedule and will support growth initiatives across key areas, including small molecules for human and animal health, fermentation, peptides, gene therapy, and antibody-drug conjugates (ADCs).

Management commentary

Dr Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, said the company delivered record quarterly revenue along with improved profitability, driven by increasing commercial deliveries in CDMO and sustained performance in affordable medicines.
He added that the company continued to strengthen its integrated offerings and specialised capabilities, while achieving key milestones, including entering into agreements to in-license two antibody-drug conjugates and the final handover of a new land parcel to support future expansion.

Stock performance and technical outlook

Laurus Labs shares have delivered strong returns over the medium and long term. The stock has gained around 45% in the last three months and surged nearly 92% over the past year. The company currently commands a market capitalisation of approximately Rs 86,505 crore.

From a technical perspective, the stock’s 14-day Relative Strength Index (RSI) stands at 66.3, indicating strong momentum while remaining below the overbought zone of 70. The stock is trading above all eight key simple moving averages (SMAs), reflecting a positive trend.

Institutional interest rises

FIIs increased their stake in Laurus Labs during the June 2026 quarter, with holdings rising from 25.82% to 28%, indicating stronger institutional interest in the stock.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

This article was written by

Analyst’s Disclosure: I/we have a beneficial long position in the shares of IONQ, INFQ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Shares of Vedanta-backed Sterlite Technologies rallied as much as 5% to their day’s high of Rs 592 on the BSE on Monday after international brokerage CLSA upgraded the stock to Outperform and assigned a target price of Rs 950, implying an upside of 68% from current market levels.

It’s been an unforgettable year for Sterlite Tech shareholders as the stock has rocketed 466% in 2026 alone.

What is CLSA saying?

The brokerage said Sterlite Technologies’ order book surged 155% QoQ to Rs 18,600 crore, pointing to a strong growth outlook. Factoring in the company’s recent Rs 1,500 crore QIP fundraising and the significant Q1 FY27 beat, CLSA raised its forecasts by 7-125% for FY27-29CL. The brokerage now sees Sterlite Technologies delivering a 62% EBITDA CAGR.
Sterlite Tech secured a multi-year contract worth $1.11 billion, or more than Rs 10,000 crore, to supply optical connectivity products for next-generation AI data centres. The company also received multiple hyperscaler orders worth more than $100 million for Neuralis, its integrated data centre solutions portfolio. It also won a strategic order to supply long-haul, dark-fibre high-density micro-cables to a major connectivity infrastructure provider.

Also read: Forget selling! FIIs doubled down on this AI multibagger stock that’s up 200% YTD

The order wins come as data centres require higher fibre density, faster data transmission and more efficient connectivity systems to handle AI workloads. STL has been positioning itself as a supplier of optical fibre, cables and integrated connectivity products for this buildout.

Sterlite Tech said it achieved a net debt-free balance sheet during the quarter after raising Rs 1,500 crore through a qualified institutional placement.
The company said the fundraise has strengthened its balance sheet and will help support the next phase of growth. Following the improvement in its financial position, CRISIL revised its rating outlook to “Stable”, while ICRA upgraded the company’s credit rating to “AA (Stable)”.The balance-sheet improvement is important for STL as it enters a larger order execution cycle. A stronger capital base gives the company more room to scale production, invest in products and manage working capital as orders rise.

Sterlite Tech Q1 results

Sterlite Technologies reported its strongest quarterly performance in Q1FY27, helped by higher demand for optical connectivity products, growth in its data centre business and a record order book linked to AI-ready digital infrastructure.

The company reported revenue of Rs 1,910 crore for the quarter ended June 30, up 87% from Rs 1,019 crore in the same quarter last year. Sequentially, revenue rose 33% from Rs 1,441 crore in Q4FY26. Profit after tax rose 870% to Rs 197 crore from Rs 10 crore a year earlier. In the March quarter, the company had reported PAT of Rs 59 crore.

Read more: AI, data centre boom powers these 9 stocks up to 477% in 2026. Can you still join the party?

EBITDA rose to Rs 397 crore, compared with Rs 140 crore in Q1 and Rs 218 crore in the previous quarter. EBITDA margin stood at 20.8%, the highest in nearly 20 quarters, helped by a better product mix, operating leverage and higher contribution from the data centre business.

STL Managing Director Ankit Agarwal said Q1 FY27 was the strongest quarter in the company’s history, with record revenue and profitability reflecting the strength of its AI-ready digital infrastructure portfolio and the trust placed by hyperscalers and telecom operators.
He said the rapid scale-up of the Data Center business shows how decisively STL has aligned itself with the AI infrastructure buildout. With a record order book and strong customer trust, the company expects to continue delivering innovative and reliable solutions to support its customers’ growth.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Shares of Dr Lal PathLabs jumped nearly 8% on Monday to hit a new 52-week high after the diagnostics firm reported better-than-expected earnings for the first quarter of FY27, with multiple brokerages raising target prices.

Dr Lal PathLabs shares jumped to a fresh 52-week high of Rs 1,895 apiece on Monday, rising more than 12% in just two sessions. The stock is on track to record its sharpest single-day surge since early May this year.

The company on Friday reported a 28% year-on-year (YoY) increase in consolidated net profit to Rs 169.5 crore for the April-June quarter of FY27, from Rs 132.4 crore in the corresponding quarter of the previous financial year. The firm’s revenue from operations, meanwhile, rose over 19% YoY to Rs 797.7 crore during the quarter under review.

Along with the Q1 results, Dr Lal PathLabs announced an interim dividend of Rs 5 per equity share for the ongoing financial year 2027, with July 30 fixed as the record date to determine the eligibility of shareholders to receive the payout.

Also read |Dr Lal PathLabs posts higher first-quarter profit on healthy demand for tests

Nomura on Dr Lal PathLabs share price

Nomura maintained its ‘Buy’ call on the shares of Dr Lal PathLabs but increased its target price to Rs 2,085 apiece from Rs 1,860 apiece. The latest target price implies an upside potential of 18.5% from the stock’s previous closing price of Rs 1,759.20 apiece.

The international brokerage said that the company’s Q1 earnings came ahead of its estimates. The beat was driven primarily by higher-than-expected realisations, aided by price hikes in the CGHS and ECHS schemes, it said, noting that management indicated that the benefit from the CGHS and ECHS price hikes should continue over the next 2–3 quarters.
For FY27, the company’s management has raised its revenue guidance to mid-teens from early-teens, implying an acceleration in growth on the back of stronger realisation. On margins, management has adopted a more conservative stance, maintaining EBITDA margin guidance at 27–28% as it intends to reinvest in capacity building while prioritising growth, Nomura said. “We, however, model FY27 revenue growth of 16.6% and an EBITDA margin of 28.9%. Beyond network expansion, a target of 12–15 lab additions in FY27, the company is investing in high-end tests, radiology and international market opportunities, with inorganic growth also on the table,” it further said.Nomura revised its FY27 estimates to reflect the strong Q1 results, factoring in higher revenue growth and lower EBITDA margins. Consequently, it raised its FY27F–29 earnings estimates by nearly 6%. “We believe Dr Lal PathLabs’ valuation is underpinned by strong volume growth and a robust balance sheet that supports its acquisition ambitions. We expect Dr Lal PathLabs to trade at least at the upper end of its pre-COVID range of 40–45x one-year-forward EPS. A higher market valuation, versus pre-COVID, stronger earnings growth, 18% EPS CAGR over FY26–29F versus 14% over FY16–19, and a higher dividend payout justify this valuation, in our view,” the international brokerage said.

Nuvama on Dr Lal PathLabs share price

Nuvama also noted that Dr Lal PathLabs beat earnings estimates. It said the company remains on a robust growth path owing to network expansion, 12–15 labs and 2–4 radiology centres in FY27, CGHS and ECHS price hike-led growth, sustained traction in the Delhi NCR market, double-digit growth, and a strong Suburban turnaround, along with a robust balance sheet which could unlock inorganic optionality.

The brokerage raised its earnings estimates for FY27 and FY28. It maintained its ‘Buy’ rating on the stock while increasing its target price to Rs 2,140 apiece. This implies an upside potential of nearly 22%.

JM Financial on Dr Lal PathLabs share price

JM Financial said Dr Lal delivered a strong Q1FY27, beating estimates by a substantial margin and delivering a second consecutive quarter of 15%+ growth. “We remain positive on Dr Lal, supported by its market leadership, structurally superior B2C mix, healthy cash generation and revival of structural growth in the industry,” it said.

The domestic brokerage maintained its ‘Buy’ call on Dr Lal PathLabs shares but increased its target price to Rs 2,195 apiece, implying nearly 25% upside.

Also read |Why is market rising today? Sensex soars 600 points, Nifty above 23,900. 6 key factors driving the rally

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)